Company Overview and News

to your dashboard

Headline News

Healthcare ETF (VHT) Hits New 52-Week High

2017-10-21 zacks
Investors seeking momentum may have Vanguard Healthcare ETF (VHT - Free Report) on radar now. The fund recently hit a new 52-week high. Shares of VHT are up approximately 29.2% from the 52-week low of $120.38/share. (63-0)

Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update

2017-10-20 seekingalpha
Alibaba Group Holdings,, Visa Inc., Apple Inc., and Johnson & Johnson are the largest five individual stock positions. (1097-1)

Johnson & Johnson Does It Again

2017-10-20 seekingalpha
I’ve been very upbeat on Johnson & Johnson (JNJ) lately and fortunately for me, that sentiment came at just the right time. JNJ has taken off higher this year and after a very well-received Q3 report from earlier this week, it is flying to yet another new high. I have to admit, however, that it seems to be getting to the point where it may be fully priced in the low-$140s and in this article, I’ll walk through why I think that. (5-0)

These Funds Will Triple Your Income in 2018

2017-10-19 investorplace
I’m going to get straight to brass tacks. Let’s discuss 2 closed-end funds with up to 18% upside in the next 12 months, plus yields up to 5.8%. Both are leading a blockbuster trend almost everyone has missed. (131-0)

Is It Time To Take Profits On Johnson & Johnson?

2017-10-19 seekingalpha
Due to recent appreciation, the company's dividend yield is now relatively low. Making matters worse, dividend growth has been slowing in recent years. (5-0)

Healthcare ETFs Head to Head: XLV vs. VHT

2017-10-19 zacks
The healthcare sector has been in the spotlight lately. President Donald Trump targeted drug companies and accused them of charging extremely high prices (read: ETFs in Focus as IMF ups Global Growth Forecast). (11-0)

Retiring In Your 50s Might Be Easier Than You Think

2017-10-19 seekingalpha
Many people have no idea that they can retire in their 50s. So they keep on working. (5-0)

Healthcare ETFs in Focus on Johnson & Johnson Q3 Earnings

2017-10-19 zacks
Shares of Johnson & Johnson (JNJ - Free Report) increased 3.5% at market close on Oct 17, 2017 after beating the Zacks Consensus Estimate on both earnings and revenues. The company’s revenues of $19.7 billion increased 10.3% in third-quarter 2017 on a year-over-year basis and 4.5% on a sequential basis. It came ahead of the consensus mark of $19.28 billion. (11-0)

Can ImmunoGen's Key Pipeline Cancer Candidate Drive Growth?

2017-10-19 zacks
On Oct 18, 2017, we issued an updated report on ImmunoGen, Inc. (IMGN - Free Report) . (107-0)

Varian Medical (VAR) Initiates Halcyon Treatment in Europe

2017-10-19 zacks
Strengthening its focus on image-guided volumetric intensity modulated radiotherapy to cancer patients, Varian Medical Systems Inc. (VAR - Free Report) announced that it has initiated treatment with its latest Halcyon radiotherapy treatment system in Europe. Notably, treatment was provided to an 80-year-old male with head and neck cancer at Belgium-based University Hospitals Leuven (UZ Leuven) just two months after the hospital had ordered the new system. (9-0)

Market Is Not Waiting For Tax Reform - Cramer's Mad Money (10/18/17)

2017-10-19 seekingalpha
US Treasury Secretary Steven Mnuchin said that the tax reform is baked into the market and if it doesn't go through, it will impact stocks negatively. Cramer thinks otherwise. "Look, I appreciate he's trying to get Congress motivated, but just on the facts, I think he's quite wrong. The truth is, most executives don't believe tax reform is coming. It's simply not integral to this market. Yes, they've lost faith," he said. (156-1)

Earnings Review and Free Research Report: Johnson & Johnson EPS increased 13.0%; Revenue Advanced 10.3%

2017-10-19 accesswire
LONDON, UK / ACCESSWIRE / October 19, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Johnson & Johnson (NYSE: JNJ), which can be viewed by registering at, following the Company's release of its financial results on October 17, 2017, for the third quarter fiscal 2017. The healthcare Company's revenue and earnings numbers topped market estimates. (20-0)

J&J: Unattractive

2017-10-19 seekingalpha
JNJ surged above $140 on a "beat" and raised non-GAAP EPS guidance after releasing Q3 earnings on Tuesday. (270-1)

What to Expect from Big Pharmas After J&J's Solid Q3 Results?

2017-10-18 zacks
Johnson & Johnson (JNJ - Free Report) was the first large-cap pharma stock to report its earnings results for this season on Oct 17. J&J beat the Zacks Consensus Estimate for both earnings and revenues in the third quarter and also raised its 2017 sales and profit outlook. Shares of J&J were up more than 3% on Tuesday. (23-0)

Dow ETFs Soar as the Index Hits 23,000

2017-10-18 zacks
A fair share of the buoyancy in Wall Street this year can be attributed to the Dow Jones Industrial Average. The blue-chip index has been continually hitting record highs, with the latest being the 23,000-mark touched on Oct 17. The index actually set out on an astounding rally since Trump’s win and crossed a “new 1,000-point threshold for the fourth time this year.” (230-0)

Johnson & Johnson: Fully Priced As Operating Momentum Accelerates

2017-10-18 seekingalpha
I have long liked J&J for its responsible operations as well as discipline regarding leverage and M&A, which is paying off nowadays when some peers get burned. (360-0)

Your Daily Pharma Scoop: AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?

2017-10-18 seekingalpha
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (389-0)

Dow Jones Industrial Average Hits 23,000. Now What? | InvestorPlace

2017-10-18 investorplace
On Oct. 18, the Dow Jones Industrial Average hit a new all-time intraday high of 23,145 as of this writing. Investors who aren’t playing the indices can gain exposure to the Dow Jones today through the SPDR Dow Jones Industrial Average ETF (NYSEARCA:DIA). With the index up 16.3% in 2017, though, how much longer can this rally continue? (364-0)

Impact Of FASB's Pension Cost Accounting Rule Change

2017-10-18 seekingalpha
The Financial Accounting Standards Board introduced a new accounting standard that requires companies to present service cost as the only operating component of periodic pension costs on the income statement. (5-0)

Analysts Piling On to Raise Johnson & Johnson Price Targets Higher and Higher

2017-10-18 247wallst
Johnson & Johnson (NYSE: JNJ) is one of those Dow Jones Industrial Average companies that seems to just keep chugging ever higher over time. The company has greatly exceeded its expectations so far in 2017, and prior years have been good for the medical and consumer products giant as well. (7-0)

Only 16 Of 61 Are 'Safer' Dividend Healthcare Dogs For October

2017-10-18 seekingalpha
Top "safer" dividend Healthcare dog, GSK's 16.2% net gain was 58% more than MRK's 10.4% second place effort, and 100% over PFE's fourth place result per analyst targets 10/13/17. (91-0)

Stock Market News For Oct 18, 2017

2017-10-18 zacks
Benchmarks finished higher on Tuesday after a slew of strong corporate earnings led gains for healthcare stocks. Both the Dow and the S&P 500 closed at record levels, with the blue-chip index touching the psychological 23,000 milestone for the first time in its 120-year history. Meanwhile, industrial production for September rebounded after two straight months in the lull. (76-0)

Johnson & Johnson At All-Time Highs: Time To Sell Or To Buy?

2017-10-18 seekingalpha
The company has done what it does often: Johnson & Johnson beat analyst estiamtes once again. (8-0)

Johnson & Johnson: One-Time Bumps

2017-10-18 seekingalpha
Before the open, Johnson & Johnson (JNJ) reported Q3 results that at first glance appear amazing. Investors though need to consider the one-time benefits before getting too excited about this stock trading at an expensive multiple. (5-0)

Johnson & Johnson: Q3 Beat Was Low Quality

2017-10-18 seekingalpha
Johnson & Johnson reported better than expected Q3 2017 results, but mainly thanks to non-operating items. (5-0)

CUSIP: 047816010